Calidi Biotherapeutics, Inc. (CLDI)

Calidi Biotherapeutics, Inc. (CLDI) Healthcare & Pipeline Overview

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company pioneering cell-based delivery platforms for oncolytic viruses, targeting high-grade gliomas and metastatic solid tumors. Their innovative approach seeks to improve treatment efficacy and patient safety in the competitive biotechnology landscape, addressing unmet needs in cancer therapy.

What Is the Investment Thesis for CLDI?

Calidi Biotherapeutics presents a compelling investment thesis centered on its innovative cell-based delivery platforms for oncolytic viruses. The company's approach aims to enhance the efficacy and safety of cancer treatments, addressing a significant unmet need in the oncology space. With a pipeline including NeuroNova for high-grade gliomas and SuperNova for metastatic solid tumors, Calidi is targeting challenging cancer indications with significant market potential. Key value drivers include successful clinical trial outcomes, strategic partnerships, and regulatory approvals. The company's focus on allogeneic stem cells offers potential advantages in terms of scalability and cost-effectiveness. A beta of 1.42 indicates higher volatility compared to the market. Upcoming clinical trial data for NeuroNova and SuperNova will be critical catalysts. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company's market capitalization is $0.00B as of 2026-05-04.

Based on FMP financials and quantitative analysis

CLDI Key Highlights

• Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing cell-based delivery platforms for oncolytic viruses.
• The company's lead product candidates, NeuroNova and SuperNova, target high-grade gliomas and advanced metastatic solid tumors, respectively.
• Calidi's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses, potentially enhancing efficacy and improving patient safety.
• The company was founded in 2014 and is based in San Diego, California, indicating a relatively young but focused organization.
• Calidi's approach aims to overcome the limitations of traditional cancer therapies by providing more effective and targeted treatment options.

Who Are CLDI's Competitors?

CLDI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CLDI's Key Strengths?

• Innovative cell-based delivery platforms.
• Targeting unmet needs in cancer treatment.
• Experienced management team.
• Promising early clinical data.

What Are CLDI's Weaknesses?

• Clinical-stage company with no approved products.
• Limited financial resources.
• High risk of clinical trial failures.
• Dependence on key personnel.

What Could Drive CLDI Stock Higher?

• Clinical trial data readouts for NeuroNova in high-grade gliomas.
• Clinical trial data readouts for SuperNova in advanced metastatic solid tumors.
• Potential for strategic partnerships and collaborations.
• Advancement of pipeline through clinical development.

What Are the Key Risks for CLDI?

• Clinical trial failures.
• Regulatory hurdles and delays.
• Competition from established pharmaceutical companies.
• Limited financial resources.
• Dependence on key personnel.

What Are the Growth Opportunities for CLDI?

• Expansion into New Therapeutic Areas: Calidi Biotherapeutics has the opportunity to expand its cell-based delivery platform to target other cancer types beyond high-grade gliomas and metastatic solid tumors. By exploring new oncology indications, such as lung cancer, breast cancer, and melanoma, Calidi can significantly increase its market potential. This expansion could involve developing new oncolytic virus payloads or modifying its stem cell delivery platform to target specific tumor microenvironments. The market for targeted cancer therapies is substantial, with each new indication representing a multi-billion dollar opportunity. Timeline: 2-3 years for preclinical development and initiation of clinical trials.
• Strategic Partnerships and Collaborations: Calidi can accelerate its growth by forming strategic partnerships with pharmaceutical companies, research institutions, and other biotechnology firms. These collaborations can provide access to funding, expertise, and resources, enabling Calidi to advance its pipeline and expand its commercial reach. Partnerships could involve co-development agreements, licensing deals, or joint ventures. The value of such partnerships can range from millions to hundreds of millions of dollars, depending on the scope and potential of the collaboration. Timeline: Ongoing, with potential for new partnerships to be announced within the next year.
• Advancement of Clinical Trials: The successful advancement of NeuroNova and SuperNova through clinical trials is critical for Calidi's growth. Positive clinical trial data will validate the efficacy and safety of its cell-based delivery platform, attracting further investment and paving the way for regulatory approvals. Each phase of clinical development represents a significant milestone, with the potential to increase the company's valuation. The market for effective cancer therapies is substantial, with premium pricing for innovative treatments. Timeline: Ongoing, with key clinical trial readouts expected in the next 12-24 months.
• Securing Regulatory Approvals: Obtaining regulatory approvals from agencies such as the FDA and EMA is essential for commercializing Calidi's products. Regulatory approvals will allow Calidi to market and sell its therapies to patients, generating revenue and establishing a sustainable business. The regulatory pathway for cancer therapies is rigorous, requiring extensive clinical data and manufacturing controls. The market exclusivity granted by regulatory approvals provides a significant competitive advantage. Timeline: 3-5 years, depending on clinical trial outcomes and regulatory review processes.
• Expansion of Manufacturing Capabilities: As Calidi's pipeline advances, the company will need to expand its manufacturing capabilities to meet the anticipated demand for its products. This expansion may involve building new manufacturing facilities or outsourcing production to contract manufacturing organizations (CMOs). Scalable and cost-effective manufacturing processes are essential for ensuring the commercial viability of Calidi's therapies. The market for cell-based therapies is growing rapidly, with increasing demand for high-quality manufacturing services. Timeline: 2-3 years, with ongoing investments in manufacturing infrastructure.

What Opportunities Does CLDI Have?

• Expansion into new therapeutic areas.
• Strategic partnerships and collaborations.
• Securing regulatory approvals.
• Advancement of clinical trials.

What Threats Does CLDI Face?

• Competition from established pharmaceutical companies.
• Regulatory hurdles.
• Clinical trial failures.
• Economic downturn.

What Are CLDI's Competitive Advantages?

• Proprietary cell-based delivery platforms for oncolytic viruses.
• Strong intellectual property portfolio protecting its technology.
• Clinical-stage pipeline with promising early results.
• Experienced management team with expertise in immuno-oncology.

What Does CLDI Do?

Founded in 2014 and based in San Diego, California, Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company dedicated to developing innovative immunotherapies for cancer treatment. The company focuses on advancing a potent allogeneic stem cell platform capable of delivering anti-tumor payloads to various oncology indications, including high-grade gliomas and solid tumors. Calidi's core technology revolves around cell-based delivery platforms designed to protect, amplify, and potentiate oncolytic viruses, ultimately enhancing efficacy and improving patient safety. Their pipeline includes NeuroNova, which utilizes allogeneic neural stem cells loaded with an oncolytic adenovirus for treating high-grade gliomas, and SuperNova, which employs allogeneic adipose-derived mesenchymal stem cells loaded with the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. By leveraging these innovative platforms, Calidi aims to overcome the limitations of traditional cancer therapies and provide more effective and targeted treatment options for patients with challenging cancers. The company's focus on allogeneic stem cells allows for off-the-shelf availability, potentially reducing manufacturing complexities and treatment timelines compared to autologous cell therapies. Calidi's strategic approach positions it as a key player in the evolving field of immuno-oncology, with a commitment to developing next-generation cancer therapies.

What Products and Services Does CLDI Offer?

• Develop immunotherapies for cancer treatment.
• Advance allogeneic stem cell platforms for delivering anti-tumor payloads.
• Design cell-based delivery platforms to protect and amplify oncolytic viruses.
• Develop NeuroNova for the treatment of high-grade gliomas.
• Develop SuperNova for the treatment of advanced metastatic solid tumors.
• Focus on enhancing efficacy and improving patient safety in cancer treatment.

How Does CLDI Make Money?

• Develop and commercialize cell-based immunotherapies for cancer.
• Generate revenue through sales of approved therapies.
• Establish strategic partnerships and collaborations for co-development and licensing.
• Secure funding through venture capital, grants, and public offerings.

What Industry Does CLDI Operate In?

Calidi Biotherapeutics operates within the rapidly evolving immuno-oncology market, a segment of the biotechnology industry focused on harnessing the body's immune system to fight cancer. The market is characterized by intense competition, with numerous companies developing novel therapies, including checkpoint inhibitors, CAR-T cell therapies, and oncolytic viruses. Calidi's unique approach, utilizing cell-based delivery platforms for oncolytic viruses, positions it as a potential disruptor in the field. The global immuno-oncology market is projected to reach billions of dollars in the coming years, driven by the increasing prevalence of cancer and the demand for more effective and less toxic treatments. Calidi's success will depend on its ability to demonstrate clinical efficacy and safety, secure regulatory approvals, and establish strategic partnerships.

Who Are CLDI's Key Customers?

• Patients with high-grade gliomas.
• Patients with advanced metastatic solid tumors.
• Hospitals and cancer treatment centers.
• Oncologists and other healthcare professionals.

CLDI Financials

CLDI Latest News

CLDI Analyst Consensus

CLDI MoonshotScore

Common Questions About CLDI (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources